NMDA Receptor Antagonist
Memantine for Cognitive Impairment in SLE
This trial is testing memantine, a drug that blocks certain brain receptors, in people with Systemic Lupus Erythematosus (SLE) who have a specific genetic variant. The goal is to see if memantine can safely and effectively reduce cognitive symptoms in these patients. Memantine is used to treat memory and thinking problems and has been investigated for similar issues in SLE patients.
Mucolytic Agent
N-acetylcysteine for Lupus
This trial is a phase II study to test the safety and efficacy of N-acetyl cysteine (NAC) in treating systemic lupus erythematosus (SLE). SLE is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. This study will have two groups of 105 subjects each, with one group continuing the tolerated dosage of NAC and the other group switched to placebo capsules. The study will last 13 months with seven study visits per subject. Each subject will donate approximately 100 ml of blood
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Cutaneous Lupus Erythematosus
This trial is testing a new medication called deucravacitinib to help people with certain types of lupus that aren't well managed by current treatments. The medication works by calming the immune system to reduce skin damage.
Popular Filters
Trials for Lupus Nephritis Patients
Monoclonal Antibodies
Daratumumab for Lupus Nephritis
This trial is testing daratumumab, a medication that helps the immune system, in patients with active lupus nephritis. The goal is to see if it can help these patients by reducing kidney damage caused by their disease.
Monoclonal Antibodies
Ravulizumab for Lupus Nephritis and IgA Nephropathy
This trial is testing the safety and effectiveness of a drug called ravulizumab, given through a vein, in patients with specific kidney diseases. The drug aims to reduce kidney damage by blocking part of the immune system.
Corticosteroid
Obinutuzumab + Standard Therapy for Lupus Nephritis
This trial tests if adding obinutuzumab to standard treatments is safe and effective for patients with severe kidney inflammation from lupus. It helps the immune system remove harmful cells and has shown better results in kidney health compared to standard treatments alone.
Monoclonal Antibodies
Ianalumab + Standard Therapy for Lupus Nephritis
This trial will test how well ianalumab injections work and how safe they are for adults with a type of kidney inflammation caused by lupus. The medication is given under the skin at regular intervals. It aims to reduce kidney inflammation by calming the immune system.
Trials for LN Patients
Monoclonal Antibodies
Daratumumab for Lupus Nephritis
This trial is testing daratumumab, a medication that helps the immune system, in patients with active lupus nephritis. The goal is to see if it can help these patients by reducing kidney damage caused by their disease.
Monoclonal Antibodies
Ravulizumab for Lupus Nephritis and IgA Nephropathy
This trial is testing the safety and effectiveness of a drug called ravulizumab, given through a vein, in patients with specific kidney diseases. The drug aims to reduce kidney damage by blocking part of the immune system.
Corticosteroid
Obinutuzumab + Standard Therapy for Lupus Nephritis
This trial tests if adding obinutuzumab to standard treatments is safe and effective for patients with severe kidney inflammation from lupus. It helps the immune system remove harmful cells and has shown better results in kidney health compared to standard treatments alone.
Monoclonal Antibodies
Ianalumab + Standard Therapy for Lupus Nephritis
This trial will test how well ianalumab injections work and how safe they are for adults with a type of kidney inflammation caused by lupus. The medication is given under the skin at regular intervals. It aims to reduce kidney inflammation by calming the immune system.
Trials for ANA Positive Patients
Monoclonal Antibodies
Nipocalimab for Lupus
This trial is testing nipocalimab, a special medicine that blocks harmful parts of the immune system, in people with active lupus. The goal is to see if it can reduce inflammation and prevent further damage caused by the disease.
Monoclonal Antibodies
Subcutaneous Anifrolumab for Lupus
This trial is testing an injectable medication called anifrolumab in adults with moderate-to-severe lupus who haven't fully responded to standard treatments. Anifrolumab works by reducing the immune system's attack on the body to help lessen lupus symptoms. It has been approved for the treatment of moderate to severe systemic lupus erythematosus (SLE) based on evidence from various studies.
Monoclonal Antibodies
Belimumab for Lupus
This trial is testing a medication called belimumab, given as an injection under the skin, in children with lupus. The goal is to see if it is safe and effective by calming down their overactive immune systems. Belimumab is approved for the treatment of lupus in adults with moderate disease activity.
Monoclonal Antibodies
Obinutuzumab for Lupus
This trial is testing a medication called obinutuzumab in people with active lupus who have specific antibodies in their blood. These patients are already on standard treatments but need more help. The medication works by reducing harmful immune cells that cause inflammation and damage.
Trials for Anti-dsDNA Positive Patients
Monoclonal Antibodies
Belimumab for Lupus
This trial is testing a medication called belimumab, given as an injection under the skin, in children with lupus. The goal is to see if it is safe and effective by calming down their overactive immune systems. Belimumab is approved for the treatment of lupus in adults with moderate disease activity.
Monoclonal Antibodies
Obinutuzumab for Lupus
This trial is testing a medication called obinutuzumab in people with active lupus who have specific antibodies in their blood. These patients are already on standard treatments but need more help. The medication works by reducing harmful immune cells that cause inflammation and damage.
Monoclonal Antibodies
Mosunetuzumab for Lupus
This trial is testing a new medication called mosunetuzumab to see if it is safe and effective for people with systemic lupus erythematosus (SLE). The medication aims to help the immune system target harmful cells, which may help reduce the symptoms of SLE.
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Lupus
This trial is testing a new medication called deucravacitinib to see if it is safe and effective for people with moderate to severe lupus, a disease where the immune system attacks the body. The medication aims to reduce inflammation by targeting specific enzymes in the immune system.
Phase 3 Trials
Anti-malarial drug
Stopping Hydroxychloroquine for Lupus
This trial is testing if older lupus patients can safely stop taking Hydroxychloroquine, a drug that reduces lupus symptoms but can harm the eyes over time. The study focuses on patients aged 60 and above who have stable disease. Researchers will monitor these patients for an extended period to see if their condition remains stable without the drug.
Monoclonal Antibodies
Subcutaneous Anifrolumab for Lupus
This trial is testing an injectable medication called anifrolumab in adults with moderate-to-severe lupus who haven't fully responded to standard treatments. Anifrolumab works by reducing the immune system's attack on the body to help lessen lupus symptoms. It has been approved for the treatment of moderate to severe systemic lupus erythematosus (SLE) based on evidence from various studies.
Corticosteroid
Obinutuzumab + Standard Therapy for Lupus Nephritis
This trial tests if adding obinutuzumab to standard treatments is safe and effective for patients with severe kidney inflammation from lupus. It helps the immune system remove harmful cells and has shown better results in kidney health compared to standard treatments alone.
Monoclonal Antibodies
Ianalumab + Standard Therapy for Lupus Nephritis
This trial will test how well ianalumab injections work and how safe they are for adults with a type of kidney inflammation caused by lupus. The medication is given under the skin at regular intervals. It aims to reduce kidney inflammation by calming the immune system.
Monoclonal Antibodies
Obinutuzumab for Lupus
This trial is testing a medication called obinutuzumab in people with active lupus who have specific antibodies in their blood. These patients are already on standard treatments but need more help. The medication works by reducing harmful immune cells that cause inflammation and damage.
Trials With No Placebo
Behavioral Intervention
Integrated Care Management for Lupus
This trialwill study lupus patients at BWH to identify those at high risk of adverse outcomes, and offer intensive care management to reduce avoidable ED visits, hospitalizations and improve high quality care.
Behavioral Intervention
Chronic Disease Self-Management Program for Systemic Lupus Erythematosus
This trial examines if a health education program can improve health and reduce healthcare use in African American women with lupus. The program involves regular sessions that teach practical skills for managing health problems. Researchers want to see if this helps these women better manage their condition. This community-based education program is designed to help participants gain confidence and skills to better manage their chronic conditions; it has been implemented worldwide.
Monoclonal Antibodies
Daratumumab for Lupus Nephritis
This trial is testing daratumumab, a medication that helps the immune system, in patients with active lupus nephritis. The goal is to see if it can help these patients by reducing kidney damage caused by their disease.
View More Related Trials
Frequently Asked Questions
Introduction to lupus
What are the top hospitals conducting lupus research?
Lupus, an autoimmune disease that affects millions of people worldwide, has sparked a surge in clinical trials aimed at finding new treatments and interventions. In Oklahoma City, the Oklahoma Medical Research Foundation leads the charge with seven ongoing lupus trials. This innovative facility is dedicated to unraveling the mysteries of this complex condition and paving the way for improved management options. SUNY Upstate Medical University in Syracuse also plays a vital role in lupus research, currently conducting six active clinical trials. Researchers here are committed to discovering breakthroughs that can alleviate the burden of this chronic illness on patients' lives.
In Dallas, the Metroplex Clinical Research Center is actively involved in five lupus trials, striving to uncover better ways to diagnose and treat this challenging condition. Meanwhile, at the Medical University of South carolina in Charleston, researchers are working diligently on five ongoing clinical studies focused on lupus intervention and management strategies.
Finally, NYU Langone Health joins these esteemed institutions with four active lupus trials taking place within its walls. Located in New york City—a hub for medical innovation—NYU Langone Health is part of a vibrant community committed to advancing our understanding of autoimmune diseases like lupus.
These hospitals stand as beacons of hope for individuals living with lupus across the United States and beyond. Through their dedication and tireless efforts, they strive not only to improve treatment options but also offer promising avenues towards a future where individuals affected by this debilitating disease can lead fuller lives.
Which are the best cities for lupus clinical trials?
When it comes to lupus clinical trials, several cities emerge as leaders in research and innovation. New york City boasts 33 active trials, focusing on treatments like Hydroxychloroquine (HCQ), Deucravacitinib, and CC-97540 administration. Miami, Florida follows closely with 29 ongoing studies exploring Nipocalimab, ALPN-101, and GLPG3667 as potential therapies. Houston, Texas is also a hub for lupus clinical trials with 25 active studies investigating treatments such as ALPN-101 and Cenerimod. These cities offer individuals living with lupus access to cutting-edge research that may lead to improved outcomes and better management of this autoimmune disease.
Which are the top treatments for lupus being explored in clinical trials?
Lupus, a complex autoimmune disease, is being targeted by several noteworthy treatments currently undergoing clinical trials. At the forefront of research is belimumab, an established medication that has shown promising results and continues to be explored in ongoing studies. Another contender is baricitinib, a newer drug with potential benefits for lupus patients. Additionally, voclosporin—an immunosuppressant—has also emerged as a treatment option worthy of investigation. These innovative therapies offer hope for individuals living with lupus and may pave the way for improved management of this challenging condition.
What are the most recent clinical trials for lupus?
Exciting advancements in lupus research offer hope for improved treatment options. Recent clinical trials have explored various therapeutic approaches to tackle this complex autoimmune disease. In one study, BMS-986326 Dose 1 IV was investigated in Phase 1, showing promise as a potential treatment option. Another trial focused on Imvotamab (Dose Escalation), aiming to evaluate its efficacy and safety profile in lupus patients. Additionally, the effectiveness of the Herpes Zoster Subunit (HZ/su) Vaccine is being examined in Phase 4 to provide valuable insights into its use for individuals with lupus. Furthermore, Study 3 examines Upadacitinib Dose A's impact on lupus patients and holds potential as an innovative therapy option. These ongoing efforts signal progress in understanding and addressing lupus, offering renewed hope for those affected by this condition.
What lupus clinical trials were recently completed?
Recently completed clinical trials in the field of lupus have shown promising advancements in our understanding and treatment of this complex autoimmune disease. Notably, a trial sponsored by GlaxoSmithKline investigating Anifrolumab reached its completion, offering potential new options for patients. Additionally, a study led by Pfizer explored the efficacy of PF-04965842 as a therapeutic approach for lupus patients. These recent milestones highlight the ongoing efforts to improve outcomes and quality of life for individuals battling with lupus.